Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil plus corticosteroids versus placebo plus corticosteroids for newly diagnosed chronic graft-versus-host disease
2023-505394-32-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing Belumosudil plus corticosteroids with Placebo plus corticosteroids (2 arms). Primary endpoint: Event-Free Survival. Planned start Mar 2024; status: authorised.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2023-505394-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505394-32-00.